查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1891802

全球藥物輸送裝置市場：依給藥途徑、應用、最終用戶和地區劃分 - 市場規模、行業趨勢、機會分析和預測（2026-2035 年）

Global Drug Delivery Devices Market: By Route of Administration, Application, End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

藥物輸送裝置市場正從穩定成長過渡到快速擴張期，反映出醫療保健產業日益增長的複雜性和創新性。 2025 年，該市場規模約為 2,126 億美元，預計到 2035 年將成長近一倍，達到約 4,507 億美元。這一成長意味著 2026 年至 2035 年預測期內的複合年增長率 (CAGR) 為 7.8%，顯示在多種因素的共同推動下，市場呈現持續上升趨勢。

推動市場快速擴張的主要因素之一是生物療法的廣泛應用，生物療法在多種疾病的治療中發揮越來越重要的作用。生物製劑的複雜性要求開發先進的注射裝置，以便安全有效地傳遞這些強效藥物，通常還需要精確的劑量控制和可控的釋放機制。為此，製造商正在不斷創新，研發用於這些先進療法的新型給藥系統，推動了對專業藥物傳輸技術的需求。

值得關注的市場趨勢

藥物輸送裝置的競爭格局呈現出大型多元化醫療公司和專業創新企業並存的動態格局。這些企業正透過各種策略鞏固其市場地位，包括併購、大力投資研發、建立策略聯盟。這些發展正在推動產業整合，重塑競爭格局，並加劇爭奪不斷擴大的市場佔有率的競爭。

2025年12月，飛利浦醫療（Phillips Medisize）——一家以其在藥物輸送、體外診斷和醫療器械的設計、開發、工程和製造方面的專業知識而聞名的Molex公司——將在著名的 "肺部藥物輸送" 大會（DDL 2025）上重點展示其吸入式藥物輸送裝置和製劑平台。本次展覽將展示飛利浦醫療在推動吸入療法（藥物傳輸技術的關鍵領域）的創新承諾和能力。

2025年10月初，Enable Injections宣布與Incyte建立重要的合作關係。 Incyte是一家領先的生物製藥公司，根據InvestingPro報道，其估值達178億美元，財務狀況穩健。此合作的重點在於利用Enable公司的enFuse體外給藥系統，開發並交付Incyte的在研療法。

同月，全球領先的藥物封裝、藥物遞送和診斷解決方案提供者Stevanat集團宣布大幅擴大其藥物遞送系統產能。此舉反映了該公司積極應對不斷增長的市場需求，並順應了擴大產能以滿足醫療保健行業不斷變化的需求的更廣泛趨勢。

核心成長驅動因子

藥物遞送設備市場的發展趨勢與需要頻繁、甚至終身服藥的慢性疾病的增加密切相關。糖尿病、肥胖等慢性疾病以及需要複雜治療方案的癌症已成為藥物遞送設備的主要需求來源。近年來，這些疾病的治療方案發生了顯著變化，許多患者已過渡到每週一次的自我注射。這項變更推動了對易於使用、可靠且能支持患者自主用藥和依從性的給藥裝置的需求。

新機遇

給藥裝置市場正迅速向 "高價值解決方案" 類別轉型，其特點是具備數位連接能力和複雜藥物治療方案管理能力。這些先進的裝置旨在輸送藥物，並提供即時監測、數據採集以及與數位健康平台整合等高級功能。這一轉變反映了個人化醫療和互聯醫療的更廣泛趨勢，患者和醫療服務提供者都將受益於更精準、更具互動性的治療方案。

優化障礙

嚴格的監管要求對給藥裝置市場的成長構成重大挑戰。美國食品藥物管理局 (FDA) 等監管機構制定了嚴格的標準，以確保所有進入市場的產品符合嚴格的安全性、有效性和品質標準。雖然這些法規對於保護患者健康和維護大眾對醫療技術的信任至關重要，但它們也為尋求推出創新裝置的製造商帶來了重大障礙。

目錄

第一章：摘要整理：全球藥物傳輸設備市場

第二章：研究方法與架構

  • 研究目標
  • 產品概述
  • 市場區隔
  • 質性研究
    • 一手和二手資料來源
  • 量化研究
    • 一手和二手資料來源
  • 依地區劃分的原始調查受訪者
  • 研究假設
  • 市場規模估算
  • 資料三角驗證

第三章：全球藥物傳輸設備市場概論

  • 產業價值鏈分析
    • 材料供應商
    • 製造商
    • 經銷商
    • 終端用戶
  • 行業展望
  • PESTLE 分析
  • 波特五力分析
    • 供應商議價能力
    • 買方議價能力
    • 替代品威脅
    • 新進入者威脅
    • 競爭強度
  • 市場成長與展望
    • 市場收入估計與預測（2020-2035）
    • 價格趨勢分析
  • 市場吸引力分析
    • 依細分市場/地理劃分
    • 可操作的洞見（分析師建議）

第四章 競爭格局儀錶板

  • 市場集中度
  • 公司市佔率分析（價值，2025 年）
  • 競爭格局及基準分析

第五章：全球藥物輸送裝置市場分析

  • 市場動態與趨勢
    • 成長驅動因素
    • 其他因素
    • 機遇
    • 主要趨勢
  • 市場規模及預測（2020-2035 年）
    • 依給藥途徑
    • 依應用
    • 依最終用戶
    • 依地區

第六章：北美藥物輸送裝置市場分析

第七章：歐洲藥物輸送裝置市場分析

第八章：亞太地區藥物輸送裝置市場分析

第九章：中東及非洲藥物輸送裝置市場分析

第十章：南美洲藥物輸送裝置市場分析

第十一章：公司簡介

  • Becton, Dickinson and Company
  • 3M
  • Antares Pharma
  • Bayer AG
  • Cipla Inc.
  • Enable Injections
  • F. Hoffmann-La Roche Ltd
  • Gerresheimer AG
  • GlaxoSmithKline plc
  • Insulet Corporation
  • Johnson &Johnson Services, Inc.
  • MEDMIX SYSTEMS AG
  • Merck &Co., Inc.
  • Novartis AG
  • Novosanis
  • OraSure Technologies, Inc.
  • Pfizer Inc.
  • Sanofi
  • SMC Ltd.
  • Sulzer Ltd
  • ViVO Smart Medical Devices Ltd.
  • West Pharmaceutical Services, Inc.
  • Other Prominent Players

第12章 附錄

簡介目錄
Product Code: AA12251594

The drug delivery devices market has moved beyond a phase of steady growth into a period of rapid expansion, reflecting the increasing complexity and innovation within the healthcare sector. Valued at approximately US$212.6 billion in 2025, the market is projected to nearly double in size, reaching an estimated valuation of US$450.7 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 7.8% over the forecast period from 2026 to 2035, indicating a strong and sustained upward trajectory driven by multiple converging factors.

One of the primary drivers behind this rapid market expansion is the proliferation of biologic therapies, which have become increasingly central to the treatment of a wide range of diseases. The complexity of biologics requires the development of advanced injectable devices capable of delivering these potent medications safely and effectively, often with precise dosing and controlled release mechanisms. In response, manufacturers are innovating new delivery systems that accommodate these sophisticated therapies, fueling demand for specialized drug delivery technologies.

Noteworthy Market Developments

The competitive landscape of the drug delivery devices market is characterized by a dynamic mix of large, diversified healthcare corporations alongside specialized innovators. These players employ a variety of strategies to strengthen their market positions, including mergers and acquisitions (M&A), significant investments in research and development (R&D), and the formation of strategic partnerships. Such activities are driving consolidation within the industry, reshaping the competitive hierarchy, and intensifying the race to capture larger shares of the expanding market.

In December 2025, Phillips Medisize, a Molex company renowned for its expertise in the design, development, engineering, and manufacturing of pharmaceutical drug delivery, in vitro diagnostic, and medtech devices, is set to highlight its inhaled drug delivery device and formulation platforms at the prestigious Drug Delivery to the Lungs conference (DDL 2025). This showcase will demonstrate Phillips Medisize's commitment to innovation and its capacity to advance the capabilities of inhalation therapies, a critical segment within drug delivery technology.

Earlier, in October 2025, a significant partnership was announced between biopharmaceutical giant Incyte, a company valued at $17.8 billion with strong financial health according to InvestingPro analysis, and Enable Injections. The collaboration focuses on leveraging Enable's enFuse On-Body Delivery System to develop and deliver Incyte's investigational therapies.

During the same month, Stevanato Group, a global leader providing drug containment, drug delivery, and diagnostic solutions across the pharmaceutical, biopharmaceutical, and life sciences sectors, announced a substantial expansion of its drug delivery system manufacturing capacity. This move reflects the company's proactive approach to meeting growing market demand and underscores the broader trend of scaling production capabilities to support the evolving needs of the healthcare industry.

Core Growth Drivers

The trajectory of the drug delivery devices market is closely intertwined with the rising prevalence of chronic diseases that necessitate frequent, often lifelong, medication dosing. Chronic conditions such as diabetes and obesity have emerged as the leading consumers of drug delivery devices, alongside cancer, which also requires complex therapeutic regimens. In recent years, treatment protocols for these diseases have evolved significantly, with many patients now shifting toward weekly self-injections. This change has increased the demand for user-friendly, reliable delivery devices that support patient autonomy and adherence to therapy.

Emerging Opportunity Trends

The drug delivery devices market is increasingly shifting toward what is known as "High-Value Solutions," a category of devices characterized by digital connectivity and the ability to manage complex drug formulations. These advanced devices are designed not only to deliver medication but also to provide enhanced functionality such as real-time monitoring, data collection, and integration with digital health platforms. This shift reflects a broader trend toward personalized medicine and connected healthcare, where patients and providers benefit from more precise and interactive treatment options.

Barriers to Optimization

Stringent regulatory requirements represent a major challenge to the growth of the drug delivery devices market. Regulatory agencies like the US Food and Drug Administration (FDA) impose rigorous standards designed to ensure that every product entering the market meets strict criteria for safety, efficacy, and quality. These regulations are essential to protect patient health and maintain trust in medical technologies, but they also create considerable hurdles for manufacturers seeking to introduce innovative devices.

Detailed Market Segmentation

By Route of Administration, Oral administration stands out as the undisputed leader in the drug delivery devices market, largely due to its unparalleled convenience and widespread acceptance among patients and healthcare providers alike. This route of administration offers a non-invasive, easy-to-use method for delivering medications, making it the preferred choice for a broad range of treatments. Its dominance is further reinforced by the vast number of small-molecule drugs, which are particularly well-suited for oral delivery because of their chemical properties and stability.

By Application, Cancer has emerged as the leading application within the drug delivery devices market due to the unique challenges associated with treating malignancies. Effective cancer treatment often requires the precise administration of highly potent and toxic biologic drugs, making accurate dosing and controlled delivery essential to maximize therapeutic outcomes while minimizing harmful side effects. The complexity of oncology therapies, which frequently involve targeted treatments and immunotherapies, has heightened the demand for advanced drug delivery devices capable of managing these sensitive medications with exceptional precision and safety.

By End User, Hospitals represent the largest end-user segment in the drug delivery devices market, primarily because they handle the highest volume of acute care procedures that demand the use of complex infusion systems. These procedures often require precise and reliable delivery of medications, fluids, and other therapies, making advanced drug delivery devices indispensable within hospital settings. The critical nature of hospital care, where timely and accurate drug administration can significantly impact patient outcomes, drives substantial demand for sophisticated delivery tools designed to meet stringent safety and efficacy standards.

Segment Breakdown

By Route of Administration

  • Oral
  • Ocular
  • Inhalation
  • Nasal
  • Injectable
  • Topical
  • Others

By Application

  • Cardiovascular
  • Diabetes
  • Cancer
  • Infectious Diseases
  • Others

By End User

  • Hospitals
  • Ambulatory Services
  • Home Healthcare

By Region

  • North America
  • The US
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia and New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a commanding position in the global drug delivery devices market, capturing a dominant market share of approximately 32.72% in 2025. This leadership is deeply rooted in the region's robust and structural growth driven by the rapid commercial expansion of high-value biologics. The increasing adoption of biologic therapies, which are often complex and require specialized delivery mechanisms, has significantly fueled the financial growth of the drug delivery devices sector in North America. This surge in therapeutic consumption underscores the region's pivotal role as a global hub for advanced healthcare solutions.
  • Beyond merely consuming these innovative therapies, North America is experiencing a manufacturing renaissance aimed at reshaping its pharmaceutical production landscape. There is a strong strategic push to localize manufacturing capabilities, bringing production closer to the regional market. This shift not only enhances supply chain resilience but also accelerates the delivery of advanced drug delivery devices to patients. By investing in state-of-the-art manufacturing technologies and infrastructure within its borders, North America is reinforcing its dominance in the drug delivery devices market.

Leading Market Participants

  • Becton, Dickinson and Company
  • 3M
  • Antares Pharma
  • Bayer AG
  • Cipla Inc.
  • Enable Injections
  • F. Hoffmann-La Roche Ltd
  • Gerresheimer AG
  • GlaxoSmithKline plc
  • Insulet Corporation
  • Johnson & Johnson Services, Inc.
  • MEDMIX SYSTEMS AG
  • Merck & Co., Inc.
  • Novartis AG
  • Novosanis
  • OraSure Technologies, Inc.
  • Pfizer Inc.
  • Sanofi
  • SMC Ltd.
  • Sulzer Ltd
  • ViVO Smart Medical Devices Ltd.
  • West Pharmaceutical Services, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Drug Delivery Devices Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Drug Delivery Devices Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Material Provider
    • 3.1.2. Manufacturer
    • 3.1.3. Distributor
    • 3.1.4. End User
  • 3.2. Industry Outlook
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Segment/Region
    • 3.6.2. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Drug Delivery Devices Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Route of Administration
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Oral
        • 5.2.1.1.2. Ocular
        • 5.2.1.1.3. Inhalation
        • 5.2.1.1.4. Nasal
        • 5.2.1.1.5. Injectable
        • 5.2.1.1.6. Topical
        • 5.2.1.1.7. Others
    • 5.2.2. By Application
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Cardiovascular
        • 5.2.2.1.2. Diabetes
        • 5.2.2.1.3. Cancer
        • 5.2.2.1.4. Infectious Diseases
        • 5.2.2.1.5. Others
    • 5.2.3. By End User
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Hospitals
        • 5.2.3.1.2. Ambulatory Services
        • 5.2.3.1.3. Home Healthcare
    • 5.2.4. By Region
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. North America
          • 5.2.4.1.1.1. The U.S.
          • 5.2.4.1.1.2. Canada
          • 5.2.4.1.1.3. Mexico
        • 5.2.4.1.2. Europe
          • 5.2.4.1.2.1. Western Europe
  • 5.2.4.1.2.1.1. The UK
  • 5.2.4.1.2.1.2. Germany
  • 5.2.4.1.2.1.3. France
  • 5.2.4.1.2.1.4. Italy
  • 5.2.4.1.2.1.5. Spain
  • 5.2.4.1.2.1.6. Rest of Western Europe
          • 5.2.4.1.2.2. Eastern Europe
  • 5.2.4.1.2.2.1. Poland
  • 5.2.4.1.2.2.2. Russia
  • 5.2.4.1.2.2.3. Rest of Eastern Europe
        • 5.2.4.1.3. Asia Pacific
          • 5.2.4.1.3.1. China
          • 5.2.4.1.3.2. India
          • 5.2.4.1.3.3. Japan
          • 5.2.4.1.3.4. South Korea
          • 5.2.4.1.3.5. Australia & New Zealand
          • 5.2.4.1.3.6. ASEAN
          • 5.2.4.1.3.7. Rest of Asia Pacific
        • 5.2.4.1.4. Middle East & Africa
          • 5.2.4.1.4.1. UAE
          • 5.2.4.1.4.2. Saudi Arabia
          • 5.2.4.1.4.3. South Africa
          • 5.2.4.1.4.4. Rest of MEA
        • 5.2.4.1.5. South America
          • 5.2.4.1.5.1. Argentina
          • 5.2.4.1.5.2. Brazil
          • 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Drug Delivery Devices Market Analysis

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Route of Administration
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country

Chapter 7. Europe Drug Delivery Devices Market Analysis

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Route of Administration
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country

Chapter 8. Asia Pacific Drug Delivery Devices Market Analysis

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Route of Administration
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country

Chapter 9. Middle East & Africa Drug Delivery Devices Market Analysis

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Route of Administration
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country

Chapter 10. South America Drug Delivery Devices Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Route of Administration
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Becton, Dickinson and Company
  • 11.2. 3M
  • 11.3. Antares Pharma
  • 11.4. Bayer AG
  • 11.5. Cipla Inc.
  • 11.6. Enable Injections
  • 11.7. F. Hoffmann-La Roche Ltd
  • 11.8. Gerresheimer AG
  • 11.9. GlaxoSmithKline plc
  • 11.10. Insulet Corporation
  • 11.11. Johnson & Johnson Services, Inc.
  • 11.12. MEDMIX SYSTEMS AG
  • 11.13. Merck & Co., Inc.
  • 11.14. Novartis AG
  • 11.15. Novosanis
  • 11.16. OraSure Technologies, Inc.
  • 11.17. Pfizer Inc.
  • 11.18. Sanofi
  • 11.19. SMC Ltd.
  • 11.20. Sulzer Ltd
  • 11.21. ViVO Smart Medical Devices Ltd.
  • 11.22. West Pharmaceutical Services, Inc.
  • 11.23. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators